How effective is Lynparza? What diseases can be treated

Olaparib is a targeted drug that is widely used in the treatment of a variety of solid tumors and belongs to the class of poly(ADP-ribose) polymerase (PARP) inhibitors. Its main mechanism of action is to inhibit the repair function of PARP enzyme, making it difficult for tumor cells to repair after DNA damage, and eventually undergo apoptosis. It is especially suitable for patients with BRCA gene mutations. Because of its strong targeting, Lynparza is regarded as one of the representative drugs in the era of precision treatment.

Lynparza was initially approved for the maintenance treatment of ovarian cancer in patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. By prolonging progression-free survival and reducing the need for chemotherapy, olaparib has significantly improved the quality of life in these patients, and has been listed as a standard treatment option by guidelines in many countries.

In the field of breast cancer, Lynparza is mainly used for patients with HER2-negative metastatic breast cancer who carry germline BRCA1 or BRCA2 mutations. This drug is especially suitable for use when standard chemotherapy is ineffective or when patients are intolerant to chemotherapy. As a more precise and less toxic targeted therapy, it improves the remission rate and treatment compliance.

In addition, olaparib is widely used to treat patients with metastatic castration-resistant prostate cancer (mCRPC) who have defects in theHRR (homologous recombination repair) pathway. The study found that in specific people with BRCA or ATM and other related gene mutations, olaparib can significantly extend the progression-free survival time, providing a new solution for the treatment of male reproductive system tumors.

What is more noteworthy is that olaparib has also shown potential in the treatment of metastatic pancreatic cancer. For patients carrying germline BRCA mutations, olaparib can be used as maintenance therapy to prolong disease control after receiving platinum therapy.

Reference materials:https://www.lynparza.com/